Karyopharm Therapeutics INC Form 4 insider transactions

EVP & Chief Commercial Officer of Karyopharm Therapeutics, Sohanya Cheng, sold shares of common stock to cover withholding tax liabilities related to vesting restricted stock units.

Karyopharm Therapeutics CEO Richard Paulson sold shares of KPTI stock on February 29, 2024, and March 1, 2024, to cover withholding tax liabilities related to vesting restricted stock units.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, reports acquiring 198,959 shares of common stock through restricted stock units.

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, acquired 188,205 shares of common stock through the company's 2022 Equity Incentive Plan.

Michael Mason, EVP, CFO & Treasurer of Karyopharm Therapeutics, reports the sale of 2,545 shares to cover tax obligations and the acquisition of 188,205 shares through a restricted stock unit (RSU) award.

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, reports acquiring 147,000 shares of common stock on February 28, 2024, through an award of restricted stock units.

Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, reports the acquisition of restricted stock units and disposal of common stock on February 28, 2024.

Karyopharm Therapeutics CEO Richard Paulson received 442,800 restricted stock units (RSUs) on February 28, 2024, which will vest in three equal annual installments starting February 28, 2025.